Charles Schwab’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-383,231
| Closed | -$3.46M | – | 3526 |
|
|
2025
Q4 | $3.46M | Sell |
383,231
-14,358
| -4% | -$107K | ﹤0.01% | 2588 |
|
|
2025
Q3 | $1.24M | Buy |
397,589
+50,678
| +15% | +$134K | ﹤0.01% | 2886 |
|
|
2025
Q2 | $742K | Sell |
346,911
-101,434
| -23% | -$164K | ﹤0.01% | 2998 |
|
|
2025
Q1 | $516K | Sell |
448,345
-40,372
| -8% | -$69.3K | ﹤0.01% | 3073 |
|
|
2024
Q4 | $1.07M | Buy |
488,717
+3,616
| +0.7% | +$8.19K | ﹤0.01% | 2891 |
|
|
2024
Q3 | $1.06M | Buy |
485,101
+17,898
| +4% | +$41.2K | ﹤0.01% | 2899 |
|
|
2024
Q2 | $1.08M | Buy |
467,203
+82,320
| +21% | +$342K | ﹤0.01% | 2909 |
|
|
2024
Q1 | $2.12M | Buy |
384,883
+61,693
| +19% | +$282K | ﹤0.01% | 2574 |
|
|
2023
Q4 | $798K | Sell |
323,190
-40,195
| -11% | -$382K | ﹤0.01% | 2911 |
|
|
2023
Q3 | $12.6M | Buy |
363,385
+107,997
| +42% | +$3.73M | ﹤0.01% | 1792 |
|
|
2023
Q2 | $8.38M | Buy |
255,388
+56,121
| +28% | +$1.93M | ﹤0.01% | 1988 |
|
|
2023
Q1 | $6.68M | Sell |
199,267
-506
| -0.3% | -$19.7K | ﹤0.01% | 2065 |
|
|
2022
Q4 | $6.55M | Buy |
199,773
+39,311
| +24% | +$1.16M | ﹤0.01% | 2070 |
|
|
2022
Q3 | $5.6M | Buy |
160,462
+62,900
| +64% | +$1.39M | ﹤0.01% | 2157 |
|
|
2022
Q2 | $1.19M | Buy |
97,562
+23,759
| +32% | +$355K | ﹤0.01% | 2726 |
|
|
2022
Q1 | $1M | Buy |
73,803
+2,482
| +3% | +$33.2K | ﹤0.01% | 2846 |
|
|
2021
Q4 | $1.42M | Buy |
+71,321
| New | +$1.35M | ﹤0.01% | 2796 |
|
Other funds holding VTYX
Charles Schwab's VTYX Position: Q1 2026 in Review
Charles Schwab sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 383,231 shares — an estimated $3.46M sold.
Charles Schwab first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $12.6M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Charles Schwab reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Charles Schwab sold 383,231 Ventyx Biosciences shares in Q1 2026, an estimated $3.46M.
- Charles Schwab first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Charles Schwab's Ventyx Biosciences position peaked at $12.6M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.